Advances in Pharmacological Treatment of Thoracic Malignancies

Takehito Shukuya, KAZUHISA TAKAHASHI · 2026

Read Advances in Pharmacological Treatment of Thoracic Malignancies by Takehito Shukuya, KAZUHISA TAKAHASHI (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/openalex-w7133357343.txt.

Introduction

Takehito Shukuya of Juntendo University in Tokyo wrote a 2026 review of drug treatment for cancers of the chest, above all lung cancer. Lung cancer kills more people than any other cancer worldwide. The review covers how gene testing now lets doctors match drugs to the exact changes driving each tumor.

Successive generations of targeted pills for tumors with EGFR or ALK changes have lengthened disease control, including in the brain. Antibody-drug conjugates add another option for some patients. Immune therapy now sits at the center of care for both main lung cancer types. Shukuya also reports a Japanese trial in rare thymic cancer and a new immune drug that improved survival in relapsed small cell lung cancer.

Catalog record

CREATORTakehito Shukuya, KAZUHISA TAKAHASHI
YEAR2026
COLLECTIONPAPERS
FORMATTXT
FILE SIZE31 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEOpenAlex / Juntendō Igaku/Juntendo igaku

Source: https://doi.org/10.14789/ejmj.jmj25-0049-r

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

Juntendo Medical Journal, 2026 Reviews Juntendo Medical Journal 2026 Advances in Pharmacological Treatment of Thoracic Malignancies Takehito SHUKUYA, Kazuhisa TAKAHASHI Department of Respiratory Medicine, Juntendo University School of Medicine TEL: +81-3-3813-3111 FAX: +81-3-5802-1617 E-mail: [email protected] 366th Triannual Meeting of the Juntendo Medical Society “Frontier of lung cancer treatment”〔Held on Sep. 11, 2025〕 〔Received Oct. 28, 2025〕 〔Accepted Dec. 29, 2025〕 J-STAGE Advance published date: Mar. 4, 2026 Copyright © 2026 The Juntendo Medical Society. This is an open access article distributed under the terms of Creative Commons Attribution License (CC BY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original source is properly credited. doi: 10.14789/ejmj.JMJ25-0049-R 1 Shukuya T, Takahashi K: Advances in treatment of thoracic malignancies HER2 mutations, and NTRK fusions - each account for smaller subsets, typically ranging from 1% to 7% of NSCLC cases. This molecular diversity underpins the paradigm shift toward precision oncology, where molecular testing guides therapy selection. The implementa­ tion of comprehensive next-generation sequencing (NGS) has enabled simultaneous detection of multiple actionable alterations, ensuring patients receive the most appropriate targeted therapy2). Historically, lung cancer therapy relied on plati­ num-based chemotherapy, which offered limited survival benefit (median overall survival 8-12 months for advanced disease). The advent of targeted ther­ apy-pioneered by the discovery of EGFR mutations and ALK rearrangements-has transformed NSCLC treatment. Patients with these mutations can now achieve median survivals exceeding 3-5 years with sequential tyrosine kinase inhibitors (TKIs). In parallel, immune checkpoint inhibitors (ICIs) have revolutionized the management of both NSCLC and SCLC. Anti-PD-1/PD-L1 antibodies, alone or in combination with chemotherapy, have demon­ strated unprecedented survival benefits, with longterm survival plateaus emerging in selected popu­ lations2). As shown in Figure 1, numerous drugs have been developed and introduced into clinical practice based on these backgrounds. Beyond TKIs and ICIs, a new generation of ther­ apies is being developed. These include antibodydrug conjugates (ADCs), bispecific T-cell engagers (BiTEs), chimeric antigen receptor T-cell (CAR- T) therapies, and cancer vaccines. Each modality aims to address resistance mechanisms and provide therapeutic options for patients lacking conven­ tional targets. In this review, we describe the development of molecular targeted agents which target represen­ tative driver oncogenes and advances in immuno­ therapy with the novel mechanism drugs such as bispecific antibody and ADC. EGFR-targeted therapy EGFR mutations are the most common onco­ genic drivers in NSCLC, particularly among neversmokers and East Asian patients. The two principal activating mutations-exon 19 deletions and the L858R point mutation in exon 21-account for appro­ ximately 90% of cases and lead to constitutive acti­ vation of downstream signaling pathways that promote malignant cell growth. Notably, when gefi­ tinib was first used clinically, high activity was observed in East Asian patients, never-smokers, and those with adenocarcinoma3); subsequently, somatic EGFR mutations were discovered and became the predictive biomarker guiding EGFR-TKI use - an episode that marked the dawn of molecularly targeted therapy in lung cancer5, 6). The introduction of EGFR-TKIs revolutionized treatment for this molecular subtype. The NEJ002 and WJTOG3405 phase III trials in Japan firmly established gefitinib as the standard first-line therapy for EGFR-mutated advanced NSCLC. In NEJ002, gefitinib achieved an objective response rate (ORR) Figure 1 Advances in systemic therapy for NSCLC Overview of the evolution of systemic treatments for non-small cell lung cancer, highlighting the shift from cytotoxic chemo­ therapy to targeted and immune therapies. Adapted from Guo H, et al. Biomarker-Targeted Therapies in Non-Small Cell Lung Cancer: Current Status and Perspectives. Cells. 2022 Oct 12; 11(20): 3200. 2 Juntendo Medical Journal, 2026 of 73.7% vs 30.7% (p < 0.001) and median PFS of 10.8 vs 5.4 months (HR 0.30; p < 0.001) compared with carboplatin plus paclitaxel, while OS (27.7 vs 26.6 months; p = 0.48) was confounded by treatment crossover7). Similarly, WJTOG3405 reported median PFS of 9.2 vs 6.3 months (HR 0.49; p < 0.001) and ORR of 62% vs 32% (p < 0.001) versus cisplatin plus docetaxel, confirming the superiority of EGFRTKIs despite the absence of an OS difference8). The second-generation EGFR-TKI afatinib, an irreversible ErbB family blocker, further extended disease control (PFS median 11.1 vs 6.9 months; HR 0.58; p < 0.001) and demonstrated efficacy in unco­ mmon EGFR mutations such as G719X, L861Q, and S768I9). Toxicities including diarrhea, rash, and stomatitis were frequent but manageable with proac­ tive supportive care and dose adjustment. The third-generation TKI osimertinib, developed to overcome the T790M resistance mutation, became the next therapeutic milestone. In the FLAURA trial, osimertinib significantly improved PFS (median 18.9 vs 10.2 months; HR 0.46; p < 0.001) and OS (median 38.6 vs 31.8 months; HR 0.80; p = 0.046) compared with first-generation TKIs, and demon­ strated excellent CNS activity (ORR 91%) in patients with brain metastases10). Adverse events such as rash, diarrhea, and paronychia were common, while interstitial lung disease (ILD) (3-5%) was more frequent in Japanese patients, requiring prompt recognition and management. Despite these advances, acquired resistance inev­ itably emerges. The main mechanisms of resistance include C797S mutation, MET amplification, and histologic transformation to small cell or squamous phenotypes. To address these, new therapeutic strategies are under investigation, such as fourthgeneration EGFR-TKIs targeting C797S, combina­ tion regimens incorporating EGFR and MET blockade, and bispecific antibodies. Among these, the MARIPOSA trial evaluated the bispecific EGFR/MET antibody amivantamab in combination with lazertinib, 3rd generation EGFR-TKI, versus osimertinib in treatment-naïve EGFR-mutated NSCLC. The combination achieved a superior ORR (86% vs 76%) and longer PFS (median 23.0 vs 16.6 months; HR 0.70; p < 0.001), with durable CNS control. The most common adverse events were infusion-related reactions (65%), rash, and paronychia, managed by pre-infusion prophy­ laxis and dermatologic care11). Collectively, the evolution from first- to thirdgeneration EGFR-TKIs-and now to bispecific anti­ bodies and combination approaches - illustrates a dynamic therapeutic landscape aimed at overcoming resistance and achieving more durable disease control in EGFR-mutated NSCLC. ALK-targeted therapy The anaplastic lymphoma kinase (ALK) gene rearrangement, first identified in 2007 in NSCLC, occurs in about 3-7% of adenocarcinomas, typically in younger, never- or light-smokers12). The most common fusion partner is EML4, though over 20 variants have been identified, all leading to consti­ tutive kinase activation and oncogenesis12). These alterations confer strong sensitivity to ALK-TKIs, which have transformed outcomes in this molecular subtype. Over the past decade, successive genera­ tions of ALK-TKIs have replaced chemotherapy, and many patients now achieve survival exceeding five years. The first-generation TKI crizotinib demonstrated clear superiority over chemotherapy in the PROFILE 1014 trial, showing an ORR of 74% vs 45% (p < 0.001) and median PFS of 10.9 vs 7.0 months (HR 0.45; p < 0.001)13). These results established targeted therapy as the standard of care, though limited CNS penetration and eventual resistance prompted the development of next-generation inhibitors. The second-generation ALK-TKIs, alectinib and brigatinib, produced deeper and more durable responses with excellent CNS activity. In the ALEX trial, alectinib significantly improved PFS (median 34.8 vs 10.9 months; HR 0.43; p < 0.001) and intra­ cranial ORR (81% vs 50%; p < 0.001) compared with crizotinib, resulting in a 5-year OS rate of 62.5%14). Similarly, the ALTA-1L trial demonstrated supe­ rior efficacy for brigatinib, with median PFS of 24.0 vs 11.0 months (HR 0.49; p<0.001) and strong CNS penetration15). Both agents were generally well tolerated, with

Read the complete text